Abstract
Motor outcomes after stroke relate to corticospinal tract (CST) damage. Concurrent damage from white matter hyperintensities (WMHs) might impact neurological capacity for recovery after CST injury. Here, we evaluated if WMHs modulate the relationship between CST damage and post-stroke motor impairment outcome.
We included 223 individuals from the ENIGMA Stroke Recovery Working Group. CST damage was indexed with weighted CST lesion load (CST-LL). Mixed effects beta-regression models were fit to test the impact of CST-LL, WMH volume, and their interaction on motor impairment.
WMH volume related to motor impairment above and beyond CST-LL (β = 0.178, p = 0.022). We tested if relationships varied by WMH severity (mild vs. moderate-severe). In individuals with mild WMHs, motor impairment related to CST-LL (β = 0.888, p < 0.001) with a CST-LL x WMH interaction (β = -0.211, 0.026). In individuals with moderate-severe WMHs, motor impairment related to WMH volume (β = 0.299, p = 0.044), but did not significantly relate to CST-LL or a CST-LL x WMH interaction.
WMH-related damage may be under-recognised in stroke research as a factor contributing to variability in motor outcomes. Our findings emphasize the importance of brain structural reserve in motor outcomes after brain injury.
Competing Interest Statement
A.C. was a consultant for Boehringer Ingelheim in 2021.
Funding Statement
JF receives salary support from the Canadian Institutes of Health Research (CIHR) and Michael Smith Health Research BC (HSIF-2022-2990). KSH is supported by a National Health and Medical Research Council of Australia Emerging Leadership Fellowship (2016420) and Heart Foundation Future Leader Fellowship (106607). This research was funded by the following granting agencies: Australian Heart Foundation Future Leader Fellowships (PI Brodtmann: 104748 and 100784), Canadian Institutes of Health Research (PI Boyd: PTJ-148535, MOP-130269, MOP-106651), Hospital Israelita Albert Einstein (PI Conforto: 2250-14), National Health and Medical Research Council (PI Brodtmann: GNT1020526 GNT1094974 GNT1045617), and National Institutes of Health (PI Butefisch: R21HD067906; R01NS090677; PI Conforto: R01NS076348-01; PI Liew: R01NS115845; PI Revill: R01NS090677).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from the local research ethics board of each contributing site. Written informed consent was obtained from all study participants in accordance with the Declaration of Helsinki. This study protocol was reviewed and approved by members of the ENIGMA Stroke Recovery Working Group.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data produced in the present study are available upon reasonable request to the corresponding author.